Arvinas Appoints Jared Freedberg as General Counsel
16 Enero 2024 - 4:01PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that Jared Freedberg, J.D., has joined
the company as General Counsel.
“We are thrilled to welcome Jared to Arvinas. His extensive
background in both legal and commercial functions will help provide
a unique and invaluable perspective to our team," said John
Houston, Ph.D., Arvinas Chairperson, Chief Executive Officer, and
President. “Jared's wealth of experience will be instrumental in
steering us through our first potential product commercialization
while simultaneously helping to advance our pipeline of earlier
stage assets driven by our innovative PROTAC® protein degrader
platform.”
Mr. Freedberg has over 20 years of legal and commercial
experience. Most recently he served as General Counsel at Intercept
Pharmaceuticals, where he was responsible for managing all legal
activities, including compliance, securities, corporate and board
governance, contracting, IP strategy and management, mergers and
acquisitions, business development and litigation management.
Previously, Mr. Freedberg was General Counsel, Corporate Secretary
at Immunomedics, Inc., and also served as General Counsel,
Specialty Generics and Vice President, Legal, Business Development
and Licensing at Mallinckrodt Pharmaceuticals.
“Arvinas is at the forefront of pioneering scientific
advancements in protein degradation, and I am excited to support
the company's mission to improve the lives of patients with serious
diseases,” said Mr. Freedberg. “I look forward to collaborating
with a talented team as we navigate an exciting journey ahead,
driving innovation, and achieving new milestones together.”
In connection with the commencement of Mr. Freedberg’s
employment, Arvinas granted Mr. Freedberg an option to purchase
67,314 shares of common stock and a restricted stock unit award
with respect to 45,504 shares of common stock on January 16, 2024,
as an inducement material to entering into employment with Arvinas.
The option and restricted stock units were granted in accordance
with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’
stock incentive plan.
The option has a 10-year term and an exercise price of $38.10
per share, which is equal to the closing price per share of
Arvinas’ common stock on the grant date. The option vests over four
years, with 25% of the original number of shares underlying the
option vesting on the one-year anniversary of the date of grant and
1/48th of the original number of shares vesting monthly thereafter,
and the restricted stock unit award vests in four equal
installments on each one-year anniversary of Mr. Freedberg’s
employment start date until the fourth anniversary of Mr.
Freedberg’s start date, subject to his continued service with
Arvinas through the applicable vesting dates.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs:
vepdegestrant (ARV-471) for the treatment of patients with locally
advanced or metastatic ER+/HER2- breast cancer; and ARV-766 and
bavdegalutamide for the treatment of men with metastatic
castration-resistant prostate cancer. For more information, visit
www.arvinas.com.
Arvinas Forward-Looking StatementsThis press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties, including statements regarding
the potential advantages and therapeutic benefits of vepdegestrant
(ARV-471) and potential product commercialization. All statements,
other than statements of historical facts, contained in this press
release are forward-looking statements. The words “believe,”
“expect,” “may,” “plan,” “potential,” “will,” “continue,” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words.
We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make as a result of various risks and uncertainties,
including but not limited to: our and Pfizer Inc.’s (“Pfizer”)
performance of our respective obligations with respect to our
collaboration with Pfizer; whether we and Pfizer will be able to
successfully conduct and complete clinical development for
vepdegestrant and obtain marketing approval for and commercialize
vepdegestrant on our current timelines or at all; whether our cash
and cash equivalent resources will be sufficient to fund our
foreseeable and unforeseeable operating expenses and capital
expenditure requirements; and other important factors discussed in
the “Risk Factors” section of our Annual Report on Form 10-K for
the year ended December 31, 2022, and subsequent other reports on
file with the Securities and Exchange Commission. The
forward-looking statements contained in this press release reflect
our current views with respect to future events, and we assume no
obligation to update any forward-looking statements except as
required by applicable law. These forward-looking statements should
not be relied upon as representing our views as of any date after
the date of this release.
Investor Contact:Jeff Boyle, Arvinas Investor
Relations347-247-5089Jeff.Boyle@arvinas.com
Media Contact:Kirsten Owens, Arvinas
Communications203-584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De May 2023 a May 2024